logo
Plus   Neg
Share
Email

Amgen To Acquire Five Prime Therapeutics - Quick Facts

Amgen (AMGN) has agreed to acquire Five Prime Therapeutics (FPRX) for $38.00 per share in cash, representing an equity value of approximately $1.9 billion. The acquisition includes Bemarituzumab, a phase 3 ready, first-in-class program for Gastric Cancer.

Five Prime's lead asset, bemarituzumab, is a anti-FGFR2b antibody with positive data from a randomized, placebo-controlled phase 2 study in frontline advanced gastric or gastroesophageal junction cancer.

Amgen reaffirmed its full-year outlook with revenue guidance of $25.8 to $26.6 billion and non-GAAP EPS guidance of $16.00-$17.00.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
South Korea's Hyundai Motor Co. announced its decision to suspend production at its Asan plant for two days starting on Monday due to a chip shortage amid the pandemic crisis, Reuters reported. The company is experiencing trouble in supply conditions for semiconductor parts for powertrain control units. The Asan factory manufactures 300,000 vehicles, including the Sonata and Grandeur sedans, each The U.S. Department of Health and Human Services is set to expand its Health Center COVID-19 Vaccine Program to include all HRSA-funded health centers. This will increase the total number of health centers that have been invited to join the program to 1,470 nationwide from the earlier 950. McDonald's Corp. is planning to hire 25,000 workers in its restaurants across Texas in April, reports said. In a three-day event from April 13 to 15, the fast-food chain is expected to hire for crew and management positions. During these hiring days, participating McDonald's restaurants in the state will be accepting applications and interviewing job seekers.
Follow RTT